Hansen Medical Announces Initiation of Sell-Side Coverage by Cowen and Company

Hansen Medical Announces Initiation of Sell-Side Coverage by Cowen and Company 
MOUNTAIN VIEW, CA -- (Marketwired) -- 06/26/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that Cowen and Company has initiated sell-side coverage of
Hansen Medical. The report was authored by Joshua Jennings, M.D.,
Director and Senior Research Analyst for medical devices.  
About Analyst Coverage of Hansen Medical 
 Hansen Medical is followed
by several analysts, including Cowen and Company. Any opinions,
estimates, forecasts or statements regarding Hansen Medical's
performance made by Cowen and Company or other analysts are theirs
alone and do not represent opinions, estimates, forecasts or
statements of Hansen Medical or its management. This press release
does not imply Hansen Medical's endorsement of or concurrence with
the information, conclusions or recommendations of Cowen and Company
or any other analyst. 
About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System, Magellan
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei(R) X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx(R) Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment of
cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.  
About Cowen and Company 
 Cowen Group, Inc. is a diversified
financial services firm and, together with its consolidated
subsidiaries, provides alternative investment management, investment
banking, research, and sales and trading services through its two
business segments: Ramius LLC and its affiliates makes up the
Company's alternative investment management segment, while Cowen and
Company, LLC is its broker-dealer segment. Its alternative investment
management products, solutions and services include hedge funds,
replication products, managed futures funds, fund of funds, real
estate, health care royalty funds and cash management services. Cowen
and Company offers industry focused investment banking for
growth-oriented companies, domain knowledge-driven research and a
sales and trading platform for institutional investors. Founded in
1918, the firm is headquartered in New York and has offices located
in major financial centers around the world. 
Investor Contacts: 
Peter J. Mariani 
Chief Financial Officer 
Hansen Medical, Inc. 
650.404.5800  
FTI Consulting, Inc.
Brian Ritchie
212.850.5683 
brian.ritchie@fticonsulting.com  
John Capodanno
212.850.5705
John.capodanno@fticonsulting.com